On Friday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) was 11.36% up from the session before settling in for the closing price of $11.71. A 52-week range for ARQT has been $1.76 – $13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 303.42%. When this article was written, the company’s average yearly earnings per share was at 64.44%. With a float of $102.94 million, this company’s outstanding shares have now reached $117.05 million.
Let’s determine the extent of company efficiency that accounts for 296 employees. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 12.05%, while institutional ownership is 102.98%. The most recent insider transaction that took place on Nov 22 ’24, was worth 162,515. In this transaction an insider of this company sold 16,023 shares at a rate of $10.14, taking the stock ownership to the 128,669 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Officer proposed sale 16,023 for $10.14, making the entire transaction worth $162,515.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.72 earnings per share (EPS) during the time that was better than consensus figure (set at -0.8) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 2.08 million, which is a drop from its year-to-date volume of 3.19 million. As of the previous 9 days, the stock’s Stochastic %D was 92.86%. Additionally, its Average True Range was 0.76.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 91.84%, which indicates a significant increase from 90.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.56% in the past 14 days, which was higher than the 66.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.68, while its 200-day Moving Average is $9.61. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $13.80. Second resistance stands at $14.57. The third major resistance level sits at $15.63. If the price goes on to break the first support level at $11.97, it is likely to go to the next support level at $10.91. Should the price break the second support level, the third support level stands at $10.14.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 117,045K outstanding shares of the company, which has a market capitalization of 1.70 billion. As of now, sales total 59,610 K while income totals -262,140 K. Its latest quarter income was 44,760 K while its last quarter net income were -41,540 K.
